Intravesical Instillation Therapy: Alternative Treatments

  • F. M. J. Debruyne
  • A. P. M. van der Meijden
  • J. A. Witjes
Conference paper
Part of the Recent Results in Cancer Research book series (RECENTCANCER, volume 126)


The high recurrence rate of superficial bladder cancer after transurethral resection (TUR) has stimulated urologists and urological investigators to explore pathways to prevent and/or reduce recurrent tumors. For more than three decades intravesical chemotherapy has been applied, and more recently intravesical immunotherapy has also been proposed. Since 20% of recurrent tumors eventually will progress and/or cause metastases, it is obvious that these forms of intravesical treatment also aim at prevention of progression and/or metastases [1,2].


Bladder Cancer Bladder Tumor Superficial Bladder Cancer Intravesical Instillation Intravesical Therapy 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Zincke H, Utz DL, Taylor WF, Myers RP, Leary FJ (1983) Influence of thiotepa and doxorubicin at time of transurethral surgical treatment of bladder cancer in tumor recurrence: a prospective, randomized, controlled trial. J Urol 129:505PubMedGoogle Scholar
  2. 2.
    Haaff EO, Dresner SM, Kelley DR, Ratliff TL, Shapiro A, Catalona WJ (1985) Role of immunotherapy in the prevention of recurrence and invasion of urothelial bladder tumors: a review. World J Urol 3:76CrossRefGoogle Scholar
  3. 3.
    Veenema RJ, Dean AL, Uso AC, Roberts M, Longo F (1969) Thiotepa bladder instillations: therapy and prophylaxis for superficial bladder tumors. J Urol 101:711PubMedGoogle Scholar
  4. 4.
    Riddle PR (1973) The management of superficial bladder tumors with intravesical epodyl. Br J Urol 45:84PubMedGoogle Scholar
  5. 5.
    Morales A, Eidinger D, Bruce AW (1976) Intracavitary bacillus Calmette-Guérin in the treatment of superficial bladder tumors. J Urol 116:180PubMedGoogle Scholar
  6. 6.
    Lamm DL, Steg A, Boccon-Gibod L, Morales A, Hanna MG Jr, Pagano F, Alfthan O, Brosman S, Fisher HAF, Jakse G, Chisholm GD, van der Meijden APM, Debruyne FMJ (1989) Complications of bacillus Calmette-Guérin immunotherapy: review of 2602 patients and comparison of chemotherapy complications. In: Debruyne FMJ, Denis L, van der Meijden APM (eds) EORTC Genito-Urinary Group monograph 6: BCG in superficial bladder cancer. Liss, New York, pp 335–355Google Scholar
  7. 7.
    van der Meijden APM, de Jong WH, de Boer EC, Steerenberg PA, Debruyne FMJ, Ruitenberg EJ (1989) Immunological aspects of intravesical administration of bacillus Calmette-Guérin (BCG) in the guinea pig. Urol Res 17:47–55PubMedCrossRefGoogle Scholar
  8. 8.
    van der Meijden APM, Steerenberg PA, van Hoogstraten IMW, Kerckhaert JA, Schreinemachers LMH, Harthoorn-Lasthuizen EJ, Hagenaars AM, de Jong WH, Debruyne FMJ, Ruitenberg EJ (1989) Immune reactions in patients with superficial bladder cancer after intradermal and intravesical treatment with bacillus Calmette-Guérin. Cancer Immunol Immunother 28:287–295PubMedCrossRefGoogle Scholar
  9. 9.
    Brosman SA, Lamm DL, Meijden APM, et al. (1989) A practical guide to the use of intravesical BCG for the management of stage Ta, T1, CIS, transitional cell cancer. In: Debruyne FMJ, Denis L, van der Meijden APM (eds) EORTC Genito-urinary Group monograph 6: BCG in superficial bladder cancer. Liss, New York, pp 311–323Google Scholar
  10. 10.
    Parmar MKB, Freedman LS, Hargreave TB, Tolley DA (1989) Prognostic factors for recurrence and follow-up policies in the treatment of superficial bladder cancer: report from the British Medical Research Council Subgroup on Superficial Bladder Cancer (Urological Cancer Working Party). J Urol 142:284–288PubMedGoogle Scholar
  11. 11.
    Cutler SJ, Heney NM, Friedell GH (1982) Longitudinal study of patients with bladder cancer: factors associated with disease recurrence and progression. In: Bonney WW, Prout GR (eds) Bladder cancer, AUA monograph, vol 1, chap 4: Williams & Wilkins, Baltimore, pp 35–46Google Scholar
  12. 12.
    Dalesio O, Schulman CC, Sylvester R, et al. (1983) Prognostic factors in superficial bladder tumors. A study of the EORTC group, GU group, J Urol 129:730–733Google Scholar
  13. 13.
    Loening S, Narayana S, Yoder L, et al. (1980) Analysis of bladder tumor recurrence in 178 patients. Urology 16:137–141PubMedCrossRefGoogle Scholar
  14. 14.
    Heney NM, Ahmed S, Flanagan MJ, et al. (1983) Superficial bladder cancer: progression and recurrence. J Urol 130:1083–1086PubMedGoogle Scholar
  15. 15.
    Smith G, Elton RA, Beynon LL, et al. (1983) Prognostic significance of biopsy results of normal-looking mucosa in cases of superficial bladder cancer. Br J Urol 55:665–669PubMedCrossRefGoogle Scholar
  16. 16.
    Lutzeyer W, Rübben H, Dahm H (1982) Prognostic parameters in superficial bladder cancer: an analysis of 315 cases. J Urol 127:250–252PubMedGoogle Scholar
  17. 17.
    Heney NM, Nocks BN, Daly JJ, et al. (1982) Ta and Tl bladder cancer: location, recurrence and progression. Br J Urol 54:152–157PubMedCrossRefGoogle Scholar
  18. 18.
    Herr HW (1991) Progression of stage Tl bladder tumors after intravesical bacillus Calmette-Guérin. J Urol 145:40–44PubMedGoogle Scholar
  19. 19.
    Morgan JDT, Bowsher W, Griffiths DFR, Matthews PN (1991) Rationalisation of follow-up in patients with non-invasive bladder tumors. A preliminary report. Br J Urol 67:158–161PubMedCrossRefGoogle Scholar
  20. 20.
    Stephenson WT, Holmes FF, Noble MJ, Gerald KB (1990) Analysis of bladder carcinoma by subsite. Cancer 66:1630–1635PubMedCrossRefGoogle Scholar
  21. 21.
    Flamm J, Dona S (1989) The significance of bladder quadrant biopsies in patients with primary superficial bladder cancer. Eur Urol 16:81–85PubMedGoogle Scholar
  22. 22.
    Tsai YC, Nichols PW, Hitti AL, Williams Z, Skinner DG, Jones PA (1990) Allelic losses of chromosomes 9, 11, and 17 in human bladder cancer. Cancer Res 50:44–47PubMedGoogle Scholar
  23. 23.
    Olumi AF, Tsai YC, Nichols PW, Skinner DG, Cain DR, Bender LI, Jones PA (1990) Allelic loss of chromosomes 17p distinguishes high grade from low grade transitional cell carcinomas of the bladder. Cancer Res 50:7061–7063Google Scholar
  24. 24.
    Sidransky D, von Eschenbach A, Tsai YC, Jones P, Summerhayes I, Marshall F, Paul M, Green P, Hamilton SR, Forst P, Vogelstein B (1991) Identification of p53 gene mutations in bladder cancers and urine samples. Science 252:706–709PubMedCrossRefGoogle Scholar
  25. 25.
    Brinquier PP, Schalken JA, Debruyne FMJ (1990) New markers for biological aggressiveness of bladder cancer: Proceedings of the 2nd International Symposium on recent advances in urological cancer diagnosis and treatment, 1990Google Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 1993

Authors and Affiliations

  • F. M. J. Debruyne
    • 1
  • A. P. M. van der Meijden
    • 1
  • J. A. Witjes
    • 1
  1. 1.Department of UrologyUniversity of NijmegenThe Netherlands

Personalised recommendations